Aquaporin A/S

Equities

AQP

DK0061555109

Water Utilities

Market Closed - Nasdaq Copenhagen 08:29:50 28/05/2024 pm IST 5-day change 1st Jan Change
18.6 DKK -0.53% Intraday chart for Aquaporin A/S +24.00% -59.57%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Transcript : Aquaporin A/S, 2023 Earnings Call, Apr 05, 2024
Aquaporin A/S Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Aquaporin A/S Provides Earnings Guidance for the Year 2024 CI
London Stocks Retreat Ahead of Final UK GDP Data for Q4 2023 MT
AstraZeneca Says Ultomiris Gets US FDA Approval to Treat Neuromyelitis Optica Spectrum Disorder MT
AstraZeneca Bags US FDA Clearance for Rare Autoimmune Disease Treatment Ultomiris MT
AstraZeneca Receives US Approval for Neuromyelitis Optica Spectrum Disorder Treatment MT
Aquaporin Announces Changes in Executive Management Team CI
Aquaporin A/S Provides Earnings Guidance for the Financial Year 2024 CI
Aquaporin A/S(CPSE:AQP) added to OMX Nordic Small Cap Index CI
Aquaporin A/S Maintains Earnings Guidance for the Full Year 2023 CI
AstraZeneca's Soliris Approved in China for Treatment of Neuromyelitis Optica Spectrum Disorder MT
AstraZeneca drug Solaris approved in China as NMOSD treatment AN
AstraZeneca's Rare Inflammatory Disease Drug for Adults Wins First-in-Class Nod in China MT
AstraZeneca working with FDA on Ultomiris risk evaluation changes AN
Transcript : Aquaporin A/S, H1 2023 Earnings Call, Aug 25, 2023
Aquaporin A/S Reaffirms Earnings Guidance for the Year 2023 CI
Aquaporin A/S Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 CI
AstraZeneca's Ultomiris wins another approval in Japan AN
AstraZeneca Wins First-in-Class Nod for Rare Inflammatory Disease Drug Ultomiris in Japan MT
Aquaporin A/S Provides Earnings Guidance of the Full Year 2023 CI
AstraZeneca's Rare Inflammatory Disease Drug Wins First-in-Class EU Approval MT
AstraZeneca's ultomiris recommended for EU approval AN
AstraZeneca's Ultomiris Recommended for Marketing Authorization in EU DJ
Correction: AstraZeneca's Rare Inflammatory Disease Drug Wins EU Health Agency's Positive Recommendation MT
Chart Aquaporin A/S
More charts
Aquaporin A/S is a Denmark-based water tech company delivering technology built on nature’s own water filtration. Aquaporin revolutionizes water purification by merging biotechnological techniques and classical engineering. The Company’s aim is to commercialize biomimetic water membranes for households and industrial use in a variety of markets and applications. Aquaporin deploys direct sales, sales through distributors and commercial partnerships. Aquaporin operates through three segments; Drinking Water, Industrial Water, and Food & Beverage. The Company’s products include: Forward osmosis membranes, Drinking water membranes, ZERO - water purifier, ONE - water purifier, Brackish water RO membranes and Aquaporin Inside technology.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
18.7 DKK
Average target price
30 DKK
Spread / Average Target
+60.43%
Consensus

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Equities
  3. AQP Stock
  4. News Aquaporin A/S
  5. Aquaporin Partners with Philips Unit for Water Purifier Technology in China